Acrivon Therapeutics, Inc. (ACRV) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$18.67M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$19.90M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$19.69M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$22.65M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$18.67M | (m) | (m) | (m) | $87.00K* | -$14.86M* | (m) | $13.84M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$19.90M | (m) | (m) | (m) | $14.00K | -$20.54M | (m) | $15.17M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$19.69M | (m) | (m) | (m) | $899.00K* | -$12.28M* | (m) | $13.65M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$22.65M | (m) | (m) | (m) | $493.00K* | -$16.61M* | (m) | $16.18M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$21.66M | (m) | (m) | (m) | $58.00K | -$19.54M | (m) | $15.41M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$25.14M | (m) | (m) | (m) | $989.00K* | -$17.32M* | (m) | $18.86M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$21.44M | (m) | (m) | (m) | $137.00K* | -$13.90M* | (m) | $15.03M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$17.67M | (m) | (m) | (m) | $815.00K | -$17.08M | (m) | $11.47M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$16.14M | (m) | (m) | (m) | $0.00* | -$9.81M* | (m) | $10.27M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$15.52M | (m) | (m) | (m) | $112.00K* | -$9.11M* | (m) | $10.52M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$14.39M | (m) | (m) | (m) | $25.00K | -$11.36M | (m) | $9.76M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$9.57M | (m) | (m) | (m) | $426.00K* | -$6.52M* | (m) | (m) | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$5.92M | (m) | (m) | (m) | $1.07M* | -$5.82M* | (m) | (m) | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$7.21M | (m) | (m) | (m) | $415.00K | -$8.42M | (m) | (m) | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$2.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$84.11M | (m) | (m) | (m) | $1.67M | -$63.66M | (m) | $59.99M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$89.20M | (m) | (m) | (m) | $2.77M | -$65.67M | (m) | $63.99M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$67.10M | (m) | (m) | (m) | $1.29M | -$42.64M | (m) | $46.02M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$32.66M | (m) | (m) | (m) | $2.17M | -$30.12M | (m) | $23.95M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$16.18M | (m) | (m) | (m) | $238.00K | -$13.98M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rallybio Corp (RLYB) | United States | $0.089B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |